7-(4-fluoro-phenyl)-2-[1-(6-methoxy-pyridin-3-ylmethyl)-4-methyl-pyrrolidin-3-yl]-3H-imidazo[5,1-f][1,2,4]triazin-4-one | 1448716-95-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 7-(4-fluoro-phenyl)-2-[1-(6-methoxy-pyridin-3-ylmethyl)-4-methyl-pyrrolidin-3-yl]-3H-imidazo[5,1-f][1,2,4]triazin-4-one
• 英文别名: 7-(4-fluorophenyl)-2-[1-[(6-methoxy-3-pyridyl)methyl]-4-methyl-pyrrolidin-3-yl]-3H-imidazo[5,1-f][1,2,4]triazin-4-one；7-(4-fluorophenyl)-2-[1-[(6-methoxypyridin-3-yl)methyl]-4-methylpyrrolidin-3-yl]-3H-imidazo[5,1-f][1,2,4]triazin-4-one
• CAS: 1448716-95-7
• 化学式: C₂₃H₂₃FN₆O₂
• 分子量: 434.473
• InChiKey: ZSDYQHTXSOIATP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  84.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE<br/>[FR] INHIBITEURS DE PDE9 COMPRENANT UN SQUELETTE IMIDAZOTRIAZINONE
  申请人：LUNDBECK & CO AS H

  公开号：WO2013110768A1

  公开（公告）日：2013-08-01

  This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula(l) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

  这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种式(I)化合物，用于治疗患有精神障碍的受试者的方法，包括向受试者施用式(I)化合物的治疗有效量。
• PDE9 inhibitors with imidazo triazinone backbone
  申请人：H. Lundbeck A/S

  公开号：US20150045348A1

  公开（公告）日：2015-02-12

  This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

  这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用式(I)化合物的治疗有效量。
• PDE9 Inhibitors with Imidazo Triazinone Backbone
  申请人：H. Lundbeck A/S

  公开号：US20160213674A1

  公开（公告）日：2016-07-28

  This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

  本发明涉及一种PDE9酶抑制剂化合物。本发明提供一种制药组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备式(I)化合物的过程。本发明还提供了一种治疗神经退行性疾病的方法，包括向患者施用式(I)化合物的治疗有效量。本发明还提供了一种式(I)化合物，用于治疗精神障碍的方法，包括向患者施用式(I)化合物的治疗有效量。
• PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE
  申请人：H. Lundbeck A/S

  公开号：EP2807163B1

  公开（公告）日：2017-03-22
• PDE9- INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE
  申请人：H. Lundbeck A/S

  公开号：EP3178820B1

  公开（公告）日：2017-12-20